The Central Drugs Standard Control Organisation on Wednesday permitted Pune-based Gennova Biopharmaceuticals to conduct Phase 1/2 clinical trials, along with animal toxicity data, for its mRNA Covid-19 vaccine candidate.
The permission was granted after the Subject expert Committee (SEC) for vaccines recommended for grant of permission in a review meeting on Wednesday, a document carrying the recommendations and accessed by IANS showed.
“After detailed deliberation, the committee recommended for grant of permission to conduct Phase 1/2 clinical trial subject to the condition that the interim results of Phase 1 study shall be submitted to the committee before proceeding to the next phase,” the document read.
The Department of Biotechnology had earlier said it has provided seed funding for the development of Gennova’s novel self-amplifying mRNA-based vaccine candidate for Covid-19.
Meanwhile, India’s total cases rise to 97,67,372 with 31,522 new infections, as per reports. Death toll mounts to 1,41,772 with 412 new deaths. Total active cases are at 3,72,293. Total discharged cases are at 92,53,306, with 37,725 new discharges in the last 24 hours.